News – Page 975 – Endpoints News

Is the $74B Celgene buyout already forcing a reckoning among Bristol-Myers Squibb’s R&D partners?

7 years ago

Oyster Point investors bet $93M on a PhIII study aimed at disrupting a major consumer market and toppling Allergan

7 years ago

Cornell researchers to launch early trial of gene therapy aimed — ultimately — at preventing Alzheimer's

7 years ago

The Roche way: Spark found a new owner who wants to buy and build a gene therapy leader

7 years ago

Temasek leads $85M round for Chinese biotech aiming for cheaper, faster, better CAR-T therapies

7 years ago

Daiichi Sankyo shakes up its R&D leadership, dispatching Junichi Koga to the US to run global ops

7 years ago

AstraZeneca, Merck notch another major Lynparza trial win — this time in pancreatic cancer

7 years ago

Additional exclusivity for a cancer treatment could cost the public $3 billion, analyst says

7 years ago

Immunomedics CEO Michael Pehl hits the exit on the heels of a CRL and accusations of a data integrity breach

7 years ago

FDA sounds the alarm on Pfizer’s blockbuster Xeljanz after a high dose was linked to a higher death rate, blood ...

7 years ago

CRISPR Therapeutics treats first patient with gene editing tech; Amicus nabs 'breakthrough' status for Pompe drug

7 years ago

Danaher hands a distressed GE $21B+ for biopharma business that made $3B last year

7 years ago

By the numbers: Top M&A deals, VC investments and pacts point to a growing hunger for gene therapy deals

7 years ago

AstraZeneca's clot-fighter Brilinta shows promise in diabetics with heart disease in big study

7 years ago

Unfazed by recent cardio setbacks, Novartis takes another PhIII challenge head-on with Akcea drug

7 years ago

Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare disease specialist Clementia

7 years ago

Roche joins the M&A game, buying gene therapy pioneer Spark for $4.3B

7 years ago

Karyopharm shares tank after FDA insiders slam their case on the efficacy of a cancer drug with “significant ...

7 years ago

Who’s in line for the next big mega-merger? Morningstar handicaps the odds among the top players

7 years ago

Days after Indivior launches authorized Suboxone generic, Mylan offers its copycat; In crowded CGRP market, Alder ...

7 years ago

AbbVie hands Voyager a mega-billions gene therapy deal, with $310M in near-term cash

7 years ago

EMA opens consultation on guideline for advanced therapies in clinical trials

7 years ago

BioMarin CEO JJ Bienaimé is planning for a blockbuster future in the gene therapy biz: to the tune of $10B to $15B a ...

7 years ago

Pfizer spinout woos Otsuka vet Raymond Sanchez to lead CNS pipeline work; Joe Anderson returns to Arix helm

7 years ago

First page Previous page 972 973 974975976 977 978 Next page Last page